Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab

NCT06003998 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

85

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer
Peritoneal Metastases

Interventions

DRUG: Irinotecan
DRUG: FOLFOX regimen
DRUG: Bevacizumab

Sponsor

Catharina Ziekenhuis Eindhoven